Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.
I often think of how I was a shadow of myself on chemotherapy this time last year, and how much stronger I am now in comparison.
This is the first FDA approval for treatment of newly diagnosed PTCL; the agency used a new program to complete the approval more quickly.
In non-small cell lung cancer, new drugs like brigatinib and crizotinib can dramatically shrink tumors with an ALK alteration.
I have felt beyond safe, loved for and cared about at Sloan — every visit, every procedure, every follow-up.
Today, 16 states require insurance plans to cover fertility preservation care when treatment like chemotherapy risks infertility.
Mutation revelation is a boon in an era of targeted therapies, say oncologists at UCSF, Children’s National Health System.
Today, instead of volunteering at my kids’ school for Halloween, I am at Sloan for my pre-op testing and meeting with the surgeon.
Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.
When each day ends, I am hopefully one step closer to defect recovery. But each day that goes by erases one from my foreshortened life.
A new area of research is examining the use of checkpoint inhibitors before surgery, a practice known as neoadjuvant therapy.
The drug could potentially stop or even destroy breast cancer tumors by attacking estrogen receptors on cancer cells.
Innovative model to drive understanding of the immune system in health and disease.
“To make a significant impact in treating this kind of cancer, we need to find it earlier,” says medical oncologist Brian Wolphin, MD, MPH...
We are proud to have supported several Damon Runyon scientists when immunotherapy was still a bold and risky investment.
Trying to encapsulate some of the truly revolutionary recent “happenings” in diagnosing and managing prostate cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.